In conclusion, synthetic lethality induced by combinatorial treatment with Axl and DDR-targeting agents might serve as a successful strategy for increased response rates in different cancer entities, even though the events vary at a molecular level between the tumor types. The gene discussed is AXL; the disease is neoplasm.